MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..
  


Agrylin (anagrelide HCL)

Company: Roberts Pharmaceutical
Approval Status: Approved December 1998
Treatment for: Cardiology
Areas: Cardiovascular / Cardiology
Possible similar drugs: Agrylin

| General Information | Side Effects |


General Information

Agrylin Capsules are indicated for the treatment of patients with Essential Thrombocythemia to reduce the elevated platelet count and the risk of thrombosis.

Agrylin Capsules are also indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.


Side Effects

These include the following: congestive heart failure, myocardial infarction, cardiomyopathy, cardiomegaly, complete heart block, atrial fibrillation, cerebrovascular accident, pericarditis, pulmonary infiltrates, pulmonary fibrosis, pulmonary hypertension, pancreatitis, gastric/duodenal ulceration, and seizure.




< back to top

Agrylin Drug Information

The Agrylin drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.





MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2014 All rights reserved.